Zdrowie i gospodarka · 08/12/2022
FDA Clears NORFLEX (Orphenadrine Citrate) for Continued Sale
The US Food and Drug Administration (FDA) has determined that NORFLEX (Orphenadrine Citrate) Injection and Extended-Release Tablet were not withdrawn from sale due to safety or effectiveness concerns, allowing the agency to continue approving abbreviated new drug applications (ANDAs) for the product.